Frontiers in antibiotic alternatives for <i>Clostridioides difficile </i>infection
Matthew Phanchana, Phurt Harnvoravongchai, Supapit Wongkuna, Tanaporn Phetruen, Wichuda Phothichaisri, Supakan Panturat, Methinee Pipatthana, Sitthivut Charoensutthivarakul, Surang Chankhamhaengdecha, Tavan Janvilisri
Abstract
multiple mechanisms. We also discuss the gaps and concerns in these developments. The next epidemic of CDI is not a matter of if but a matter of when. Therefore, being well-equipped with a collection of alternative therapeutics is necessary and should be prioritized.
Topics & Concepts
FidaxomicinClostridium difficileAntibioticsMedicineMetronidazoleDiarrheaAntibiotic-associated diarrheaAntibiotic resistanceIntensive care medicineClostridioidesVancomycinAnaerobic bacteriaPhage therapyGut floraMicrobiologyBiologyInternal medicineImmunologyBacteriaStaphylococcus aureusGeneticsEscherichia coliBacteriophageGeneBiochemistryClostridium difficile and Clostridium perfringens researchGut microbiota and healthHelicobacter pylori-related gastroenterology studies